Page last updated: 2024-12-04

2-mercaptoacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-mercaptoacetate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1133
CHEMBL ID116455
CHEBI ID30065
MeSH IDM0068267
PubMed CID5086465
CHEBI ID30066
MeSH IDM0068267

Synonyms (104)

Synonym
mercapto-acetic acid
bdbm50336509
thiovanic acid
acetic acid, mercapto-
2-thioglycolic acid
wln: sh1vq
glycolic acid, 2-thio-
.alpha.-mercaptoacetic acid
2-mercaptoacetic acid
nsc-1894
glycolic acid, thio-
nsc1894
usaf cb-35
acide thioglycolique
alpha-mercaptoacetic acid
thioglykolsaeure
sulfanylacetic acid
mercaptoessigsaeure
merkaptoessigsaeure
CHEBI:30065 ,
NCI60_001579
2-sulfanylacetic acid
acide thioglycolique [french]
hsdb 2702
kyselina thioglykolova [czech]
einecs 200-677-4
nsc 1894
thioglycollic acid
ccris 4873
un1940
brn 0506166
ai3-24151
kyselina merkaptooctova [czech]
mercaptoacetic acid
C02086
mercaptoethanoic acid
thioglycolic acid
68-11-1
thioglycolic acid, >=99%
thioglycolic acid, >=98%
inchi=1/c2h4o2s/c3-2(4)1-5/h5h,1h2,(h,3,4)
cwergrdvmfncdr-uhfffaoysa-
CHEMBL116455 ,
FT-0651867
M0052
AKOS000118940
NCGC00249103-01
mercapto acetic acid
NCGC00257153-01
tox21_303306
cas-68-11-1
dtxsid8026141 ,
dtxcid406141
tox21_201717
NCGC00259266-01
kyselina merkaptooctova
4-03-00-00600 (beilstein handbook reference)
unii-7857h94khm
7857h94khm ,
acetic acid, 2-mercapto-
kyselina thioglykolova
ec 200-677-4
thioglycolic acid [un1940] [corrosive]
FT-0628213
STL264219
thioglycolic acid [who-dd]
thioglycolic acid [inci]
thioglycolic acid [mi]
mercaptoacetic acid [hsdb]
thioglycollic acid [mart.]
hsch2cooh
hsch2co2h
2-mercaptoaceticacid
mercaptoactic acid
sulfanylacetic acid #
un 1940
mfcd00004876
thioglycolic acid, >=97%
thioglycolic acid, for synthesis, 97%
thioglycolic acid, lr, ~80%
thioglycolicacid
DB15429
Q414738
STR00166
E78850
EN300-19250
thioglycollate
sulfanylacetate
CHEBI:30066
thioglycolate(1-)
2-mercaptoacetate
mercaptoacetate
THIOGLYCOLATE ,
A836008
2-sulfanylethanoate
2-sulfanylacetate
STL280420
AKOS022139803
CWERGRDVMFNCDR-UHFFFAOYSA-M
2-mercapto-acetate
Q27104109
DTXSID301303319
513-66-6
acetic acid, mercapto-, ion(1-)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" To prevent these adverse side effects without changing the anticancer activity of the drug, we attempted to apply the two-route-infusion chemotherapy using NCS and antidotes for the NCS treatment devised by Baba."( [Screening for antagonistic agents to the lethal toxicity of neocarzinostatin. II. Effects of various drugs in inhibiting the toxicity of neocarzinostatin in vivo].
Baba, T; Matsumoto, T; Ouchi, M; Toriyama, K, 1988
)
0.27
"A no observed adverse effect level (NOAEL) was not identified for maternal toxicity in either species with the dosages tested."( Developmental toxicity evaluation of sodium thioglycolate administered topically to Sprague-Dawley (CD) rats and New Zealand White rabbits.
Jahnke, GD; Marr, MC; Myers, CB; Price, CJ; Tyl, RW; van Birgelen, AP, 2003
)
0.32
" While the potential of these products hold great promise, it is not known what potential toxic effects these nanomaterials may have on human health."( Experimental approach for an in vitro toxicity assay with non-aggregated quantum dots.
Capco, DG; Chen, Y; Crittenden, JC; Hristovski, K; Koeneman, BA; Westerhoff, P; Zhang, Y, 2009
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
" The results of a pharmacokinetic study in male Sprague-Dawley rats showed improved transport of leuprolide from thiolated NPs as compared to leuprolide solution."( Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Augustijns, P; Barthelmes, J; Bernkop-Schnürch, A; Dünnhaput, S; Iqbal, J; Laffleur, F; Perera, G; Rahmat, D; Schlocker, W; Shahnaz, G; Vetter, A, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The purpose of this study was to develop thiolated nanoparticles to enhance the bioavailability for the nasal application of leuprolide."( Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Augustijns, P; Barthelmes, J; Bernkop-Schnürch, A; Dünnhaput, S; Iqbal, J; Laffleur, F; Perera, G; Rahmat, D; Schlocker, W; Shahnaz, G; Vetter, A, 2012
)
0.38
" The relative bioavailability of optimized transdermal patch was determined and it was observed that improved bioavailability as compared to marketed conventional tablets."( Influence of chitosan thioglycolic acid conjugate in improving bioavailability of an antiparkinson drug; Rasagiline Mesylate from transdermal patch.
Rohith, G; Satheesha Babu, BK, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Dosages of 2-DG in excess of 1,500 mg/kg body mass reliably induced torpor with latencies of approximately 50 min from time of injection to a decrease in Tb below 30 degrees C; 79% of females displayed torpor at a dosage of 2,500 mg/kg."( Reduced glucose availability induces torpor in Siberian hamsters.
Dark, J; Miller, DR; Zucker, I, 1994
)
0.29
" In rabbits, maternal topical exposure to sodium thioglycolate on GD 6-29 resulted in maternal dose-related toxicity at the dosing site in all groups; no maternal systemic toxicity, embryo/fetal toxicity, or treatment-related teratogenicity were observed in any group."( Developmental toxicity evaluation of sodium thioglycolate administered topically to Sprague-Dawley (CD) rats and New Zealand White rabbits.
Jahnke, GD; Marr, MC; Myers, CB; Price, CJ; Tyl, RW; van Birgelen, AP, 2003
)
0.32
" The effect of bactericide dosage and pH on antibacterial activity of GO-Ag was examined."( Antibacterial properties and mechanism of graphene oxide-silver nanocomposites as bactericidal agents for water disinfection.
Chang, Y; Gong, J; Jiang, Y; Song, B; Zeng, G; Zhang, C, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sulfur-containing carboxylic acidAny carboxylic acid having a sulfur substituent.
monocarboxylic acid anionA carboxylic acid anion formed when the carboxy group of a monocarboxylic acid is deprotonated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
L-arginine degradation XI012
L-arginine degradation X (arginine monooxygenase pathway)119
firefly bioluminescence125

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency76.95880.000714.592883.7951AID1259369
progesterone receptorHomo sapiens (human)Potency7.02670.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency62.62560.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency70.06520.000229.305416,493.5996AID743069; AID743080
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Pseudomonas aeruginosaKi0.18000.18000.92002.4000AID575011
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID248860Inhibitory concentration that required to induce 50% decrease in PBMC (healthy human's peripheral blood cells) cells survival2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
2-[(Carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic acids selectively suppressed proliferation of neoplastic human HeLa cells. A SAR/QSAR study.
AID575011Inhibition of Pseudomonas aeruginosa beta-lactamase IMP-1 assessed as hydrolysis of nitrocefin by UV spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID247922Inhibitory concentration inducing 50% decrease in HeLa cell survival2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
2-[(Carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic acids selectively suppressed proliferation of neoplastic human HeLa cells. A SAR/QSAR study.
AID248907Inhibitory concentration that required to induce 50% decrease in PBMC+PHA (healthy human's peripheral blood cells) cells survival 2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
2-[(Carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic acids selectively suppressed proliferation of neoplastic human HeLa cells. A SAR/QSAR study.
AID1128913Inhibition of metallo-beta-lactamase IMP-1 (unknown origin)2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID1413000Binding affinity to bacterial metallo-beta-lactamase L1 expressed in Escherichia coli BL21 (DE3) treated with 2-(((4-Chlorobenzoyl)methionyl)thio)acetic acid at 2 to 10 mM after 1 hr by STD NMR method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (456)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990112 (24.56)18.7374
1990's63 (13.82)18.2507
2000's73 (16.01)29.6817
2010's183 (40.13)24.3611
2020's25 (5.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.59 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index33.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (0.21%)5.53%
Reviews1 (20.00%)6.00%
Reviews5 (1.06%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies3 (0.64%)4.05%
Observational0 (0.00%)0.25%
Observational1 (0.21%)0.25%
Other4 (80.00%)84.16%
Other461 (97.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]